Pancreatic Cancer Research

ResearcherEmory UniversityActive in the last 2 years

Mehmet Akce

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4747-7722; OpenAlex author ID A5078652492. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 0, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
41
Papers, trials and grants by year

2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: none · 2023: 1 paper, 1 trial · 2024: none · 2025: 5 papers · 2026: 4 papers

Papers 17

  1. Quantitative dynamic contrast-enhanced magnetic resonance imaging for early assessment of treatment response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00330-026-12810-2↗
  2. Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy. Co-author DOI 10.1186/s12943-026-02725-3↗
  3. ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment Co-author DOI 10.64898/2026.01.15.699725↗
  4. ADT-030, a novel PDE10 inhibitor, demonstrates potent antitumor activity in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.02.11.705411↗
  5. Emerging therapeutic advancements in pancreatic cancer: a contemporary review. Co-author DOI 10.1007/s12672-025-03027-8↗
  6. Paricalcitol plus hydroxychloroquine enhances gemcitabine activity and induces mesenchymal to epithelial transition in pancreatic ductal adenocarcinoma: A sing… Co-author DOI 10.1016/j.canlet.2025.217809↗
  7. Mechanism of enhancing chemotherapy efficacy in pancreatic ductal adenocarcinoma with paricalcitol and hydroxychloroquine. Co-author DOI 10.1016/j.xcrm.2024.101881↗
  8. Paricalcitol and hydroxychloroquine modulates extracellular matrix and enhance chemotherapy efficacy in pancreatic cancer. Co-author DOI 10.1038/s41417-025-00967-9↗
  9. ADT-1004: a first-in-class, oral pan-RAS inhibitor with robust antitumor activity in preclinical models of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12943-025-02288-9↗
  10. Survival and Prognostic Factors in Patients With Pancreatic Colloid Carcinoma Compared With Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1097/mpa.0000000000002227↗
  11. Survival Outcomes of Acinar Cell Pancreatic Cancer: A National Cancer Database Analysis. Co-author DOI 10.1097/mpa.0000000000001788↗
  12. In-hospital 30-day mortality for older patients with pancreatic cancer undergoing pancreaticoduodenectomy. Co-author DOI 10.1016/j.jgo.2019.10.012↗
  13. Young Adults With Pancreatic Cancer: National Trends in Treatment and Outcomes. Co-author DOI 10.1097/mpa.0000000000001502↗
  14. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001584↗
  15. Role of adjuvant therapy in resected stage IA subcentimeter (T1a/T1b) pancreatic cancer. Co-author DOI 10.1002/cncr.31787↗
  16. Induction Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001353↗
  17. The Potential of CAR T Cell Therapy in Pancreatic Cancer. Co-author DOI 10.3389/fimmu.2018.02166↗

Trials 1

  1. ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC) Principal investigator NCT06182072↗

Closest collaborators

The 25 strongest of 41 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Bassel F. El‐Rayes · 17 shared papers, 2018–2026 · strength 3.16
  2. Sujith Sarvesh · 7 shared papers, 2025–2026 · strength 1.70
  3. Dhana Sekhar Reddy Bandi · 7 shared papers, 2025–2026 · strength 1.70
  4. Ganji Purnachandra Nagaraju · 7 shared papers, 2025–2026 · strength 1.70
  5. Jeremy B. Foote · 5 shared papers, 2025–2026 · strength 1.14
  6. Olatunji Boladale Alese · 8 shared papers, 2019–2025 · strength 0.99
  7. Midhun Malla · 3 shared papers, 2025–2026 · strength 0.83
  8. Walid Labib Shaib · 7 shared papers, 2019–2023 · strength 0.79
  9. Ashiq Masood · 3 shared papers, 2025–2026 · strength 0.73
  10. Karina Jin Yoon · 3 shared papers, 2025–2026 · strength 0.65
  11. Zhi-Ren Liu · 2 shared papers, 2026 · strength 0.56
  12. Harrison Kim · 2 shared papers, 2026 · strength 0.51
  13. Christina Sing-Ying Wu · 4 shared papers, 2019–2023 · strength 0.46
  14. Yulia Y. Maxuitenko · 2 shared papers, 2025–2026 · strength 0.41
  15. Donald J Buchsbaum · 2 shared papers, 2025–2026 · strength 0.41
  16. Adam B. Keeton · 2 shared papers, 2025–2026 · strength 0.41
  17. Gary Anthony Piazza · 2 shared papers, 2025–2026 · strength 0.41
  18. Asfar Sohail Azmi · 2 shared papers, 2025–2026 · strength 0.41
  19. Upender Manne · 2 shared papers, 2025 · strength 0.38
  20. Julienne L. Carstens · 2 shared papers, 2025 · strength 0.38
  21. Gregory B. Lesinski · 2 shared papers, 2018–2025 · strength 0.30
  22. Ravi Chakra Turaga · 1 shared paper, 2026 · strength 0.29
  23. Shishir Kumar Maithel · 3 shared papers, 2019–2020 · strength 0.27
  24. Martin D. Holland · 1 shared paper, 2026 · strength 0.24
  25. John Bart Rose · 1 shared paper, 2026 · strength 0.24

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.